Daratumumab

Monoclonal antibody

Also known as JNJ-54767414

Biosimilars tracked: CT-P44

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Myeloma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:AL Amyloidosis · Phase 3 · investigational in the US

Also approved (2)
JP
  • Treatment of relapsed or refractory multiple myeloma
Product first approved 2017PMDA
EU
  • Multiple Myeloma Darzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma. in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5.1). in as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. Smouldering multiple myeloma Darzalex as monotherapy is indicated for the treatment of adult patients with smouldering multiple myeloma at high risk of developing multiple myeloma. Light chain (AL) amyloidosis Darzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis. Darzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
Product first approved 2016EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (50)
AL Amyloidosis
NCT06022939 · SWOG Cancer Research Network
2024-07-01 – 2030-10-29 · AL Amyloidosis
What this study did
NCT05776940 · Air Force Military Medical University, China
2023-03-31 – 2026-03-31 · Immunoglobulin Light-chain Amyloidosis
What this study did
Multiple Myeloma
NCT07887672 · Kite, A Gilead Company
2027-01 – 2042-02 · Newly Diagnosed Multiple Myeloma
What this study did
NCT04071457 · SWOG Cancer Research Network
2019-08-13 – 2040-07-01 · Multiple Myeloma
What this study did
NCT06187441 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2024-05-14 – 2037-12 · Multiple Myeloma
What this study did
NCT07649525 · University of Leeds
2026-07-03 – 2037-06 · Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
What this study did
NCT06932562 · European Myeloma Network B.V.
2025-12-23 – 2036-12 · Multiple Myeloma
What this study did
NCT06918002 · Intergroupe Francophone du Myelome
2025-07-09 – 2036-05 · Multiple Myeloma, Newly Diagnosed
What this study did
NCT07222761 · Regeneron Pharmaceuticals
2026-01-02 – 2034-08-23 · Relapsed and/or Refractory Multiple Myeloma (RRMM)
What this study did
NCT07764978 · AstraZeneca
2026-06-26 – 2034-05-12 · Newly Diagnosed Multiple Myeloma
What this study did
NCT07671287 · University of Heidelberg Medical Center
2026-06-30 – 2033-01-30 · Multiple Myeloma
What this study did
NCT06615479 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2025-03-12 – 2032-06-22 · Relapsed or Refractory Multiple Myeloma (RRMM)
What this study did
NCT05561387 · SWOG Cancer Research Network
2023-10-12 – 2031-05-30 · Plasma Cell Myeloma
What this study did
NCT03742297 · PETHEMA Foundation
2018-10-22 – 2031-01 · Newly Diagnosed Multiple Myeloma
What this study did
NCT03937635 · ECOG-ACRIN Cancer Research Group
2019-09-16 – 2029-12-31 · Smoldering Plasma Cell Myeloma
What this study did
NCT03710603 · Stichting European Myeloma Network
2018-12-14 – 2029-11 · Multiple Myeloma
What this study did
A Study of Daratumumabactive not recruiting
NCT05438043 · Janssen Research & Development, LLC
2022-12-15 – 2029-01-31 · Multiple Myeloma
What this study did
NCT04566328 · ECOG-ACRIN Cancer Research Group
2021-02-24 – 2027-12-31 · Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
What this study did
NCT06296121 · Biocad
2023-12-21 – 2026-07 · Multiple Myeloma
What this study did
NCT03836014 · Assistance Publique - Hôpitaux de Paris
2019-07-25 – 2026-07 · Multiple Myeloma in Relapse
What this study did
NCT03651128 · Celgene
2019-04-16 – 2026-04-13 · Multiple Myeloma
What this study did
NCT04288765 · Grupo Cooperativo de Hemopatías Malignas
2020-03-01 – 2025-02-28 · Multiple Myeloma
What this study did
NCT03180736 · Stichting European Myeloma Network
2017-06-14 – 2024-11-30 · Multiple Myeloma
What this study did
NCT02252172 · Janssen Research & Development, LLC
2015-02-16 – 2024-10-02 · Multiple Myeloma
What this study did
NCT03234972 · Janssen Research & Development, LLC
2017-11-30 – 2024-02-27 · Multiple Myeloma
What this study did
NCT03277105 · Janssen Research & Development, LLC
2017-10-27 – 2024-01-12 · Multiple Myeloma
What this study did
NCT02541383 · Intergroupe Francophone du Myelome
2015-09 – 2023-09-01 · Multiple Myeloma
What this study did
NCT03158688 · Amgen
2017-06-13 – 2022-04-15 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT03792620 · Grupo de Estudos Multicentricos em Onco-Hematologia
2018-11-20 – 2022-04 · Multiple Myeloma Stage I
What this study did
Other / comorbidity
NCT06867991 · The First People's Hospital of Changzhou
2024-11-08 – 2027-11-08 · Anti-N-Methyl-D-Aspartate Receptor Encephalitis
What this study did
Phase 2/3 (7)
Multiple Myeloma
NCT07887984 · Alliance for Clinical Trials in Oncology
2026-12-23 – 2053-08-01 · Multiple Myeloma (MM)
What this study did
NCT04513639 · Oslo University Hospital
2020-08-27 – 2032-06-01 · Multiple Myeloma
What this study did
NCT02419118 · Vejle Hospital
2015-01 – 2015-10-01 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07072585 · Children's Oncology Group
2026-08-28 – 2035-09-01 · Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma, T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
What this study did
NCT05403138 · Tianjin Medical University General Hospital
2022-11-01 – 2025-12-01 · Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder
What this study did
Phase 2 (173)
AL Amyloidosis
NCT07110844 · Rajshekhar Chakraborty, MD
2025-11-07 – 2033-10 · Amyloid Light-chain Amyloidosis
What this study did
NCT05898646 · Mayo Clinic
2023-09-06 – 2031-11-30 · AL Amyloidosis
What this study did
NCT07335887 · Peking University People's Hospital
2026-02-10 – 2028-08-31 · AL Amyloidosis (AL), t(11;14) Positive
What this study did
NCT04270175 · Weill Medical College of Cornell University
2021-04-14 – 2028-01 · Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
What this study did
NCT06629818 · Peking Union Medical College Hospital
2024-10-15 – 2027-03-14 · Light Chain (AL) Amyloidosis
What this study did
NCT05250973 · Janssen Research & Development, LLC
2022-03-01 – 2026-11-12 · Amyloidosis
What this study did
NCT04131309 · Stichting European Myeloma Network
2019-09-23 – 2025-01-27 · Light Chain (AL) Amyloidosis, Stage 3B
What this study did
NCT04895917 · Fondazione IRCCS Policlinico San Matteo di Pavia
2021-06-23 – 2025-01-15 · AL Amyloidosis
What this study did
NCT04474938 · Peking Union Medical College Hospital
2021-05-24 – 2024-03 · Amyloidosis; Systemic
What this study did
NCT04304144 · Alexion Pharmaceuticals, Inc.
2020-03-18 – 2023-11-14 · AL Amyloidosis
What this study did
NCT02816476 · University Hospital, Limoges
2016-09 – 2020-10 · Amyloidosis
What this study did
Multiple Myeloma
NCT07247097 · Massachusetts General Hospital
2026-08-01 – 2035-12-01 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
What this study did
NCT07107529 · European Myeloma Network B.V.
2025-12-12 – 2034-02 · Multiple Myeloma (MM)
What this study did
NCT06974786 · SCRI Development Innovations, LLC
2025-08-08 – 2033-04 · Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
What this study did
NCT04933539 · National Cancer Institute (NCI)
2022-10-31 – 2032-10-31 · Multiple Myeloma
What this study did
NCT06574126 · PETHEMA Foundation
2024-09-30 – 2032-09-30 · High Risk Smoldering Multiple Myeloma
What this study did
NCT05572229 · University Hospital, Lille
2023-12-21 – 2032-09 · Multiple Myeloma
What this study did
NCT07029776 · University of Arkansas
2027-03-01 – 2032-04-01 · Multiple Myeloma (MM)
What this study did
NCT04656951 · University of Cologne
2021-06-01 – 2031-12 · Multiple Myeloma
What this study did
NCT03289299 · International Myeloma Foundation
2018-05-25 – 2031-11-15 · Smoldering Multiple Myeloma
What this study did
NCT07764861 · Innovent Biologics (Suzhou) Co. Ltd.
2026-08-15 – 2031-06-30 · Multiple Myeloma
What this study did
NCT07830485 · Institute of Hematology & Blood Diseases Hospital, China
2026-10-15 – 2031-04-30 · Multiple Myeloma
What this study did
NCT05896228 · Benjamin T Diamond, MD
2024-02-20 – 2031-03-01 · Refractory Multiple Myeloma, Relapsed Multiple Myeloma
What this study did
DARA RVD For High Risk SMMactive not recruiting
NCT04775550 · Omar Nadeem, MD
2021-03-08 – 2030-12-08 · High-risk Smoldering Multiple Myeloma, Multiple Myeloma
What this study did
NCT06353022 · Nantes University Hospital
2024-06-26 – 2030-06-26 · Multiple Myeloma
What this study did
NCT07045909 · PETHEMA Foundation
2025-06-30 – 2030-03-31 · De Novo Multiple Myeloma, Anitocabtagene Autoleucel
What this study did
NCT06100237 · Carl Ola Landgren, MD, PhD
2023-12-04 – 2029-12-31 · Multiple Myeloma
What this study did
NCT05527340 · PETHEMA Foundation
2022-12-15 – 2029-12 · Multiple Myeloma
What this study did
NCT05231629 · University of Alabama at Birmingham
2023-12-13 – 2029-12 · Multiple Myeloma
What this study did
NCT05695508 · University of Heidelberg Medical Center
2022-12-01 – 2029-09-15 · Multiple Myeloma
What this study did
NCT05849610 · PETHEMA Foundation
2023-09-21 – 2029-07 · High-Risk de Novo Multiple Myeloma
What this study did
NCT07891923 · Tata Memorial Centre
2025-10-28 – 2029-05-05 · Newly Diagnosed Multiple Myeloma (NDMM)
What this study did
NCT06348147 · UNC Lineberger Comprehensive Cancer Center
2026-07 – 2029-05 · Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
What this study did
NCT07485647 · Eden Biltibo
2026-04-20 – 2029-04 · Multiple Myeloma
What this study did
NCT06107738 · Barbara Ann Karmanos Cancer Institute
2023-12-21 – 2028-12-31 · Multiple Myeloma
What this study did
NCT07638683 · Shanghai Zhongshan Hospital
2026-05-22 – 2028-12-30 · Multiple Myeloma, AL Amyloidosis
What this study did
NCT06505369 · North Estonia Medical Centre
2024-06-19 – 2028-10 · Multiple Myeloma
What this study did
NCT03004287 · University of Arkansas
2017-07-01 – 2028-10 · Multiple Myeloma
What this study did
NCT05497804 · Mayo Clinic
2022-09-22 – 2028-09-04 · ISS Stage III Plasma Cell Myeloma, Multiple Myeloma
What this study did
NCT04133636 · Janssen Research & Development, LLC
2019-11-07 – 2028-08-25 · Multiple Myeloma
What this study did
NCT07018050 · Qilu Pharmaceutical Co., Ltd.
2025-09-12 – 2028-07 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT04176718 · Andrew Yee, MD
2020-05-18 – 2028-05 · Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
What this study did
NCT03606577 · Nantes University Hospital
2019-07-30 – 2028-04-18 · Multiple Myeloma
What this study did
NCT04661137 · Hackensack Meridian Health
2021-03-16 – 2028-02 · Multiple Myeloma
What this study did
NCT06827860 · Larysa Sanchez
2025-11-18 – 2028-01 · Multiple Myeloma in Relapse
What this study did
NCT04756401 · Academic and Community Cancer Research United
2022-12-08 – 2027-12-30 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
Phase 1/2 (41)
AL Amyloidosis
NCT05486481 · Alfred Chung, MD
2024-01-08 – 2028-12-31 · AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease
What this study did
NCT02841033 · Boston Medical Center
2017-03-20 – 2020-07-17 · AL Amyloidosis
What this study did
Multiple Myeloma
NCT06785415 · Mayo Clinic
2025-03-18 – 2031-04-01 · Recurrent Multiple Myeloma
What this study did
NCT07681596 · AstraZeneca
2026-07-27 – 2031-03-06 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT06119685 · Indapta Therapeutics, INC.
2023-10-25 – 2029-12-31 · NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
What this study did
NCT07099391 · Memorial Sloan Kettering Cancer Center
2025-07-24 – 2029-07-24 · Multiple Myeloma
What this study did
NCT05392946 · Mayo Clinic
2022-08-11 – 2028-09-29 · Plasma Cell Myeloma
What this study did
NCT05434689 · University of Alabama at Birmingham
2023-01-18 – 2028-08 · Multiple Myeloma
What this study did
NCT02773030 · Celgene
2016-10-14 – 2028-07-28 · Multiple Myeloma
What this study did
NCT02343042 · Karyopharm Therapeutics Inc
2015-10 – 2027-04 · Multiple Myeloma
What this study did
NCT04068597 · CellCentric Ltd.
2019-08-09 – 2027-03-31 · Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
What this study did
NCT05581875 · Hellenic Society of Hematology
2022-10-20 – 2026-10-31 · Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasms, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease, Neoplasms, Plasma Cell
What this study did
NCT05280275 · Hellenic Society of Hematology
2022-04-13 – 2026-03-15 · Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease
What this study did
NCT05408026 · Alliance Foundation Trials, LLC.
2022-10-01 – 2026-02 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT05857982 · Second Affiliated Hospital of Soochow University
2023-05-20 – 2025-12-31 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT01665794 · University of Chicago
2012-08-13 – 2025-11-14 · Multiple Myeloma
What this study did
NCT06055075 · Hoffmann-La Roche
2023-12-08 – 2025-07-08 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT03732703 · Multiple Myeloma Research Consortium
2019-04-01 – 2024-12-31 · Relapsed Refractory Multiple Myeloma
What this study did
NCT01615029 · Janssen Research & Development, LLC
2012-06-26 – 2024-10-23 · Multiple Myeloma
What this study did
NCT01592370 · Bristol-Myers Squibb
2012-08-02 – 2024-07-09 · Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma
What this study did
NCT05590377 · Teva Branded Pharmaceutical Products R&D LLC
2023-01-23 – 2024-05-22 · Multiple Myeloma
What this study did
NCT04776018 · Takeda
2021-04-20 – 2023-11-09 · Relapsed and/or Refractory Multiple Myeloma (RRMM)
What this study did
NCT03481556 · Oncopeptides AB
2018-04-12 – 2022-02-02 · Multiple Myeloma
What this study did
NCT03701321 · National Cancer Institute (NCI)
2019-01-25 – 2020-05-28 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT03665155 · Memorial Sloan Kettering Cancer Center
2018-09-05 – 2020-04-20 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07075510 · University of Maryland, Baltimore
2025-10-23 – 2032-10-01 · Plasma Cell Disorder
What this study did
NCT07110662 · Hospices Civils de Lyon
2025-10-29 – 2029-04-29 · Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)
What this study did
NCT07287228 · Institute of Hematology & Blood Diseases Hospital, China
2025-12-17 – 2028-12-31 · Aplastic Anemia, Refractory, Relapse
What this study did
NCT05671757 · National Institute of Allergy and Infectious Diseases (NIAID)
2023-05-26 – 2028-05-05 · Autoimmune Disorders
What this study did
NCT04922723 · West Virginia University
2022-10-03 – 2026-12 · Glioblastoma
What this study did
NCT04827979 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-11-01 – 2026-09-10 · Highly Sensitized Prospective Kidney Transplant Recipients
What this study did
NCT05205252 · Epizyme, Inc.
2021-12-22 – 2023-07-05 · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
What this study did
NCT04204980 · Assistance Publique - Hôpitaux de Paris
2020-02-18 – 2023-06-01 · Allosensitization, Kidney Transplant Rejection, Antibody-mediated Rejection
What this study did
NCT02488759 · Bristol-Myers Squibb
2015-10-13 – 2022-10-24 · Various Advanced Cancer
What this study did
NCT03537599 · Sumithira Vasu
2020-01-10 – 2022-02-03 · Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
What this study did
NCT03023423 · Janssen Research & Development, LLC
2016-12-23 – 2019-09-26 · Carcinoma, Non-Small-Cell Lung
What this study did
Phase 1 (59)
AL Amyloidosis
NCT03283917 · M.D. Anderson Cancer Center
2018-02-07 – 2026-06-17 · Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
What this study did
Multiple Myeloma
NCT06622005 · Roswell Park Cancer Institute
2025-04-10 – 2030-04-10 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT07221032 · Medical College of Wisconsin
2026-08-05 – 2030-03 · Relapse Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT06768489 · Janssen Research & Development, LLC
2024-12-04 – 2029-06-29 · Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
What this study did
NCT07341867 · Andrew Hantel, MD
2026-07-30 – 2029-03-31 · Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood Group, Chemokine Receptor Gene C.-67T>C
What this study did
NCT04910568 · Genentech, Inc.
2021-07-26 – 2028-12-21 · Multiple Myeloma
What this study did
NCT06398457 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2024-09-19 – 2028-03 · Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
What this study did
NCT07082270 · Roswell Park Cancer Institute
2026-04-01 – 2028-02-01 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05050097 · Janssen Research & Development, LLC
2021-09-22 – 2027-12-31 · Multiple Myeloma
What this study did
NCT04108195 · Janssen Research & Development, LLC
2020-02-21 – 2027-12-31 · Multiple Myeloma
What this study did
NCT06142396 · Augusta University
2024-11-01 – 2027-11-01 · Multiple Myeloma, Renal Failure
What this study did
NCT04722146 · Janssen Research & Development, LLC
2021-03-12 – 2027-10-13 · Multiple Myeloma
What this study did
NCT05363111 · City of Hope Medical Center
2022-11-22 – 2027-03-23 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT05139225 · Memorial Sloan Kettering Cancer Center
2021-10-28 – 2026-07-01 · Multiple Myeloma
What this study did
NCT04667663 · Cancer Trials Ireland
2021-12-08 – 2026-04-30 · Multiple Myeloma
What this study did
NCT05308654 · AbbVie
2022-05-17 – 2025-12 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT05182073 · Fate Therapeutics
2021-11-10 – 2024-10-18 · Multiple Myeloma, Myeloma
What this study did
NCT05243342 · Genentech, Inc.
2022-04-28 – 2024-07-10 · Multiple Myeloma
What this study did
NCT05556616 · Teva Branded Pharmaceutical Products R&D LLC
2023-01-12 – 2024-06-04 · Multiple Myeloma
What this study did
NCT04892264 · Mayo Clinic
2021-06-03 – 2024-03-18 · Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT04121260 · Janssen Research & Development, LLC
2019-12-25 – 2023-10-13 · Multiple Myeloma
What this study did
NCT04614636 · Fate Therapeutics
2020-10-17 – 2023-08-08 · Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma
What this study did
NCT05641324 · Anaveon AG
2023-02-10 – 2023-07-12 · Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease, Hematologic Diseases
What this study did
NCT03311828 · City of Hope Medical Center
2018-02-21 – 2023-06-05 · Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma, Secondary Amyloidosis
What this study did
NCT04136756 · Nektar Therapeutics
2019-10-07 – 2023-04-24 · Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
What this study did
NCT02519452 · Janssen Research & Development, LLC
2015-10-22 – 2023-04-03 · Multiple Myeloma
What this study did
NCT03242889 · Janssen Pharmaceutical K.K.
2017-08-10 – 2023-02-10 · Multiple Myeloma
What this study did
NCT04956302 · Abdullah Khan
2021-09-27 – 2022-06-16 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT04280328 · Corvus Pharmaceuticals, Inc.
2020-02-20 – 2022-03-01 · Multiple Myeloma
What this study did
NCT02955810 · National University of Ireland, Galway, Ireland
2016-11 – 2020-11 · Multiple Myeloma
What this study did
NCT02852837 · Janssen Research & Development, LLC
2016-09-26 – 2019-12-13 · Multiple Myeloma
What this study did
NCT03068351 · Hoffmann-La Roche
2017-06-26 – 2019-08-01 · Multiple Myeloma
What this study did
NCT02497378 · Janssen Pharmaceutical K.K.
2015-07-10 – 2018-03-06 · Multiple Myeloma
What this study did
NCT02116569 · Janssen Pharmaceutical K.K.
2014-04 – 2015-09 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07513129 · M.D. Anderson Cancer Center
2026-06-05 – 2031-12-31 · T-cell Acute Lymphoblastic Leukemia, Lymphoma
What this study did
NCT04139304 · AIDS Malignancy Consortium
2021-05-24 – 2030-07 · Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
What this study did
NCT04972942 · New York Medical College
2023-05-22 – 2028-09 · T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
What this study did
NCT05749276 · Nantes University Hospital
2025-02-06 – 2028-08-06 · Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
What this study did
NCT07026604 · Beijing Tiantan Hospital
2025-07-01 – 2026-11-01 · Cavernous Malformation, Cerebral
What this study did
NCT03447808 · Jennifer Woyach
2018-08-16 – 2026-05-26 · Chronic Lymphocytic Leukemia
What this study did
NCT03473730 · M.D. Anderson Cancer Center
2018-05-29 – 2025-01-27 · Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC V8
What this study did
Phase 4 (9)
Multiple Myeloma
NCT03829371 · University of Turin, Italy
2019-01-03 – 2030-01-03 · Multiple Myeloma
What this study did
NCT07191379 · Odense University Hospital
2026-11-01 – 2028-01-01 · Multiple Myeloma in Relapse
What this study did
NCT06409702 · The First Affiliated Hospital of Soochow University
2024-06-12 – 2027-12-31 · Newly Diagnosed, High Risk, MRD, Multiple Myeloma
What this study did
NCT05511428 · Thomas Jefferson University
2022-11-08 – 2024-05-22 · Plasma Cell Myeloma
What this study did
Other / comorbidity
NCT05849740 · Institute of Hematology & Blood Diseases Hospital, China
2023-05-22 – 2027-10-31 · Acquired Hemophilia
What this study did
NCT07274462 · University Hospital, Martin
2025-11-01 – 2027-09-30 · Microvascular Inflammation - MVI in Kindey Transplant Recipients
What this study did
NCT07788456 · Institute of Hematology & Blood Diseases Hospital, China
2026-06-22 – 2027-06-30 · ITP - Immune Thrombocytopenia
What this study did
NCT05888870 · Institute of Hematology & Blood Diseases Hospital, China
2023-11-22 – 2026-12-01 · Hemophilia A With Inhibitor
What this study did
Early phase / not applicable (9)
AL Amyloidosis
NCT06192979 · Jin Lu, MD
2024-01-05 – 2027-03-31 · Amyloidosis; Systemic, AL Amyloidosis
What this study did
NCT06376214 · Nanjing University School of Medicine
2023-01-01 – 2026-12-31 · Light Chain (AL) Amyloidosis
What this study did
Multiple Myeloma
NCT06697483 · Peking University People's Hospital
2024-12-01 – 2027-12-31 · Multiple Myeloma
What this study did
NCT07721350 · Hospices Civils de Lyon
2026-10 – 2027-05 · Multiple Myeloma or Amyloidosis
What this study did
NCT07015021 · The First Affiliated Hospital of Soochow University
2025-06-01 – 2026-09-30 · Multiple Myeloma, Carfilzomib, Daratumumab, Pomalidomide
What this study did
NCT05088330 · The First Affiliated Hospital of Soochow University
2021-12-01 – 2024-12-31 · Newly Diagnosed Multiple Myeloma
What this study did
Other / comorbidity
NCT07081126 · University Hospital, Martin
2025-07-01 – 2026-12-31 · Kidney Tansplant, Acute Rejection (AR) of Transplanted Kidney
What this study did
NCT05913596 · First Affiliated Hospital of Zhejiang University
2023-05-23 – 2024-08-30 · Antibody-mediated Rejection, Kidney Tranplant
What this study did
Used as active comparator (35)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (25)
AL Amyloidosis
NCT07901725 · Regeneron Pharmaceuticals
2026-12-18 – 2035-07-25 · Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA
What this study did
Multiple Myeloma
NCT07285239 · PrECOG, LLC.
2026-12 – 2034-06 · Multiple Myeloma
What this study did
NCT07393282 · Regeneron Pharmaceuticals
2026-05-21 – 2033-07-27 · High Risk Smoldering Multiple Myeloma (HR-SMM)
What this study did
NCT07555938 · Hoffmann-La Roche
2026-06-23 – 2033-01-31 · Multiple Myeloma
What this study did
NCT06182774 · Canadian Cancer Trials Group
2024-04-10 – 2032-07-31 · Multiple Myeloma
What this study did
NCT06413498 · Kite, A Gilead Company
2024-08-23 – 2031-07 · Multiple Myeloma
What this study did
NCT06464991 · Nanjing IASO Biotechnology Co., Ltd.
2024-03-27 – 2030-12 · Multiple Myeloma
What this study did
NCT07910903 · Keymed Biosciences Co.Ltd
2026-12 – 2030-11 · Multiple Myeloma (MM)
What this study did
NCT07933432 · Qilu Pharmaceutical Co., Ltd.
2026-12-30 – 2030-05-21 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT07452198 · Genrix (Shanghai) Biopharmaceutical Co., Ltd.
2026-03-09 – 2030-03 · Multiple Myeloma
What this study did
NCT07623798 · Innovent Biologics (Suzhou) Co. Ltd.
2026-06-11 – 2029-12-31 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT06742138 · Qilu Pharmaceutical Co., Ltd.
2025-01 – 2028-12 · Multiple Myeloma
What this study did
NCT05675319 · Universitätsklinikum Hamburg-Eppendorf
2023-03-03 – 2025-03-21 · Multiple Myeloma
What this study did
Phase 2/3 (1)
Multiple Myeloma
NCT07428369 · Regeneron Pharmaceuticals
2026-06-05 – 2038-05-21 · Multiple Myeloma (MM)
What this study did
Phase 2 (1)
Multiple Myeloma
NCT06931704 · Nantes University Hospital
2025-07-09 – 2031-11-30 · Multiple Myeloma
What this study did
Phase 1/2 (3)
AL Amyloidosis
NCT05451771 · Columbia University
2022-10-26 – 2027-09 · AL Amyloidosis
What this study did
Multiple Myeloma
NCT04824794 · Genmab
2021-03-09 – 2025-07-31 · Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
What this study did
NCT03837509 · Incyte Corporation
2019-09-25 – 2022-04-05 · Relapsed or Refractory Multiple Myeloma
What this study did
Phase 1 (5)
Multiple Myeloma
NCT07400744 · Qilu Pharmaceutical Co., Ltd.
2026-03 – 2026-10 · Multiple Myeloma
What this study did
NCT05679258 · Shanghai Henlius Biotech
2023-01-31 – 2024-06-28 · Multiple Myeloma
What this study did
Other / comorbidity
NCT06371534 · Qilu Pharmaceutical Co., Ltd.
2024-04-12 – 2025-04 · Tumor
What this study did
NCT05974969 · Biocad
2023-05-17 – 2023-08-15 · Healthy
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Multiple Myeloma
NCT04649060 · Oncopeptides AB
2020-12-21 – 2022-02-07 · Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma
What this study did

Competitive landscape

This mechanism is crowded: 13 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Multiple Myeloma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Daratumumab: this drugApprovedMonoclonal antibodyCD38Partial signal
NCT03901963: Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8)
NCT02076009: Progression-free survival at the interim analysis: hazard ratio 0.37 (95% CI 0.27 to 0.52; P<0.001); 12-month PFS 83.2% with daratumumab plus lenalidomide/dexamethasone vs 60.1% with lenalidomide/dexamethasone (POLLUX, N Engl J Med 2016).
Belantamab MafodotinApprovedAntibody–drug conjugateBCMAPartial signal
NCT04246047: Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5)
NCT04162210: Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG) (Up to 27 months): Belantamab Mafodotin 11.2 Months (95% CI 6.4 to 14.5) vs Pomalidomide Plus Dexamethasone 7 Months (95% CI 4.6 to 10.6) missed
BortezomibApprovedSmall moleculeProteasomePartial signal
NCT00722566: Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73
NCT00048230: Response rate (CR+PR): 38% bortezomib vs 18% dexamethasone (P<0.001), with CR 6% vs <1%; median time to progression 6.22 vs 3.49 months (HR 0.55, P<0.001); 1-year survival 80% vs 66% (P=0.003), overall survival HR 0.57 (P=0.001).
CarfilzomibApprovedSmall moleculeProteasomePartial signal
NCT03158688: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants
NCT01568866: Progression-free Survival (From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively): Carfilzomib + DEX 18.7 months vs Bortezomib + DEX 9.4 months (95% CI 8.4 to 10.4)
Ciltacabtagene AutoleucelApprovedCell therapyBCMAPartial signal
NCT04181827: Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023).
ElotuzumabApprovedMonoclonal antibodySLAMF7 (CS1/CD319)Partial signal
NCT01335399: Progression-Free Survival (PFS) (From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)): E-Ld Cohort 31.38 Months (95% CI 26.18 to 36.8) vs Ld Cohort 29.47 Months (95% CI 23.49 to 34.3) missed
NCT01239797: Median Progression Free Survival (PFS) (From randomization up to 326 events (up to approximately 38 months)): Lenalidomide + Dexamethasone + Elotuzumab 19.35 Months (95% CI 16.62 to 22.18) vs Lenalidomide + Dexamethasone 14.85 Months (95% CI 12.09 to 17.22)
ElranatamabApprovedMultispecific antibodyBCMA x CD3Weak signalFeatured results are non-efficacy only in this race
Iberdomide (Zenbexus)ApprovedSmall moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Idecabtagene VicleucelApprovedCell therapyBCMAReliable signal
NCT03651128: PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001)
NCT03361748: Overall Response Rate (From first dose to 24 Months): BB2121 74.5% (95% CI 67.1 to 81.8)
IsatuximabApprovedMonoclonal antibodyCD38Partial signal
NCT02990338: Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279)
IxazomibApprovedSmall moleculeProteasomeReliable signal
NCT02312258: Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47)
NCT02181413: Progression Free Survival (PFS) (Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)): Ixazomib Citrate 26.5 months (95% CI 23.69 to 33.81) vs Placebo 21.3 months (95% CI 17.97 to 24.67)
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide AnalogReliable signal
NCT00424047: Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7)
NCT00056160: Time to Tumor Progression (TTP) (60 weeks (median Time To Progression of CC-5013/Dex treatment group)): CC-5013/Dex 60.1 Weeks (95% CI 41.1 to 80) vs Placebo/Dex 20.1 Weeks (95% CI 16.1 to 21.1)
LinvoseltamabApprovedMultispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Melphalan Hydrochloride (Evomela)ApprovedSmall moleculeDNA (guanine N7 position)Weak signal
NCT03159702: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. (1 year): MEL/FLU and Total-Body Irradiation (TBI) 17/43
MotixafortideApprovedPeptideCXCR4Partial signal
NCT03246529: Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel).
NCT02639559: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1 - Donors Only) (Up to Day 2): Arm 1: Donors 22/24
PlerixaforApprovedSmall moleculeCXCR4Partial signal
NCT00103662: Collection of at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses: plerixafor plus G-CSF 71.6% (106/148) vs placebo plus G-CSF 34.4% (53/154), P<.001 (DiPersio et al., Blood 2009).
PomalidomideApprovedSmall moleculeCereblon (CRBN)Partial signal
NCT01324947: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Pomalidomide 23%
NCT01311687: Progression-free Survival (PFS) - Primary Analysis (From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.): Pomalidomide Plus Low-Dose Dexamethasone 15.7 weeks (95% CI 13 to 20.1) vs High-Dose Dexamethasone 8 weeks (95% CI 7 to 9)
SelinexorApprovedSmall moleculeXPO1 (exportin-1)Partial signal
NCT03110562: SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd Arm: Selinexor + Bortezomib + Dexamethasone 13.93 Months vs Vd Arm: Bortezomib + Dexamethasone 9.46 Months (95% CI 8.11 to 10.78)
TalquetamabApprovedMultispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
TeclistamabApprovedMultispecific antibodyBCMA x CD3Partial signal
NCT05083169: Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16).
NCT04696809: Phase 2 primary endpoint ORR 76.9% (>=VGPR 76.9%, >=CR 65.4%) in 26 patients at RP2D 1.5 mg/kg; median follow-up 14.32 months
ThalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligasePartial signalFeatured results are non-efficacy only in this race
Zoledronic Acid (Zometa)ApprovedSmall moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
PanobinostatUS approval withdrawnSmall moleculeHDACPartial signal
NCT01023308: Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014)
Anitocabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
Arlocabtagene AutoleucelPhase 3Cell therapyGPRC5DWeak signalFeatured results are safety only in this race
AZD0120Phase 3Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
BCD-264Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
CevostamabPhase 3Multispecific antibodyFcRH5 (FcRL5) x CD3not yet gradedNo reviewed efficacy summary in this indication
CT-P44Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLReliable signal
NCT01345019: Time to First On-study Skeletal Related Event (From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.): Denosumab 695 days vs Zoledronic Acid 730 days (95% CI 504 to 1014)
Equecabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3Partial signal
NCT06158841: Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03).
F182112Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
FelzartamabPhase 3Monoclonal antibodyCD38Partial signal
NCT03952091: Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035)
Gamgertamig (CM336)Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
HLX15Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
IBI3003Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
InobrodibPhase 3Small moleculeCBP/p300 (bromodomain)not yet gradedNo reviewed efficacy summary in this indication
LumrotatugPhase 3Monoclonal antibodyCD38Weak signal
NCT04818372: CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days.
Mezagitamab
Phase 3(overall)
Monoclonal antibodyCD38
Weak signal(overall)
Featured results are safety only in this race
MezigdomidePhase 3Small moleculeCereblon E3 ubiquitin-ligasePartial signal
NCT05552976: Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09).
PlitidepsinPhase 3Small moleculeeEF1A2 (eukaryotic translation elongation factor 1-alpha 2)Partial signal
NCT01102426: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years): Plitidepsin+Dexamethasone 2.6 months (95% CI 1.9 to 3) vs Dexamethasone 1.7 months (95% CI 1.1 to 2)
QL2109Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
QLS32015Phase 3Multispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
QLS4131Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
RamantamigPhase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
SanritatugPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
TorutamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
TQB2934Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Velinotamig (GR1803)Phase 3Multispecific antibodyBCMA x CD3Weak signalNo reviewed efficacy summary in this indication
VenetoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Burixafor (TG-0054)Phase 2Small moleculeCXCR4Weak signal
NCT01458288: Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5
NCT01018979: Primary mobilization success: 2/4 patients in the TG-0054 2.24 mg/kg group (MM 1, NHL 1) vs 1/3 patients in the 3.14 mg/kg group (MM 1); no p-value or confidence interval reported.
CemsidomidePhase 2Small moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Hrain Anti-BCMA CAR-TPhase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
HRC0202Phase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
Iopofosine I-131Phase 2Radiopharmaceuticalphospholipid ether (selective lipid raftWeak signal
NCT02278315: The phase 1 dose-escalation and safety study enrolled 31 patients with relapsed or refractory multiple myeloma who had received a median of four prior lines of therapy. It established 31.25 mCi/m2 as the maximum tolerated single dose and identified 20 mCi/m2 administered twice, one week apart, as the highest evaluated fractionated dose regimen.
LMY-920Phase 2Cell therapyBCMA / TACInot yet gradedNo reviewed efficacy summary in this indication
RAPA-201Phase 2Cell therapyRapamycin-resistant autologous T-cell therapyWeak signal
NCT04176380: Overall response rate: 9/14 patients (64%) achieved disease remission (IMWG criteria) - 8 partial responses, 1 stringent complete response.
YKST02Phase 2Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4045Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BCMA CAR-NK (Shenzhen Pregene Biopharma)Phase 1/2Cell therapyBCMAWeak signalNo reviewed efficacy summary in this indication
BCMA-Targeted Prime CAR-T Cells (Chongqing Precision Biotech)Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BelantamabPhase 1/2Monoclonal antibodyBCMAnot yet gradedNo reviewed efficacy summary in this indication
CT071Phase 1/2Cell therapyGPRC5Dnot yet gradedNo reviewed efficacy summary in this indication
EltanexorPhase 1/2—XPO1 (exportin-1)Weak signalNo reviewed efficacy summary in this indication
EzobresibPhase 1/2Small moleculeBETnot yet gradedNo reviewed efficacy summary in this indication
Galinpepimut-SPhase 1/2VaccineWT1 (Wilms Tumor-1 protein)not yet gradedNo reviewed efficacy summary in this indication
GIC-102Phase 1/2Cell therapyAllogeneic natural killer (NK) cell therapy (non-CAR)Weak signalNo reviewed efficacy summary in this indication
HuL001Phase 1/2Monoclonal antibodyENO1 (alpha-enolase 1)not yet gradedNo reviewed efficacy summary in this indication
ICP-490Phase 1/2Small moleculeCereblon E3 ubiquitin-ligaseWeak signalNo reviewed efficacy summary in this indication
STI-6129Phase 1/2Antibody–drug conjugateCD38not yet gradedNo reviewed efficacy summary in this indication
CID-103Phase 1Monoclonal antibodyCD38Weak signalFeatured results are safety only in this race
SAR442085DiscontinuedBiologic (subtype unspecified)CD38Weak signalFeatured results are dose-finding only in this race

Large race: only the 73 furthest-along competitors are listed; 95 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

5 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(130 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Daratumumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (9)
November 2026 (3)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT04973605 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT06505369 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2026-11-30 · NCT03989414 · CT.gov ↗
What to watch
December 2026 (6)
Phase 1/2GlioblastomaActive not recruiting
Est. primary completion 2026-12 · NCT04922723 · CT.gov ↗
What to watch
Phase 2Myeloma, MultipleActive not recruiting
Est. primary completion 2026-12 · NCT04009109 · CT.gov ↗
What to watch
Phase 2Cardiac TransplantEnrolling by invitation
Est. primary completion 2026-12 · NCT05300451 · CT.gov ↗
What to watch
Phase 4Hemophilia A With InhibitorRecruiting
Est. primary completion 2026-12-01 · NCT05888870 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2026-12-31 · NCT07764861 · CT.gov ↗
What to watch
Early phase / not applicableMultiple MyelomaRecruiting
Est. primary completion 2026-12-31 · NCT06697483 · CT.gov ↗
What to watch
2027 (46)
January 2027 (3)
Phase 2AL AmyloidosisActive not recruiting
Est. primary completion 2027-01 · NCT04270175 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-01 · NCT06827860 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaActive not recruiting
Est. primary completion 2027-01-03 · NCT03829371 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-01 · NCT04268498 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-26 · NCT04133636 · CT.gov ↗
What to watch
March 2027 (6)
Phase 2Immune Thrombocytopenia, TreatmentRecruiting
Est. primary completion 2027-03 · NCT07362199 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-03 · NCT04166565 · CT.gov ↗
What to watch
Phase 4Microvascular Inflammation - MVI in Kindey Transplant RecipientsActive not recruiting
Est. primary completion 2027-03-01 · NCT07274462 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-03-08 · NCT06952478 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-03-23 · NCT05363111 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗
What to watch
April 2027 (4)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-07 · NCT04108195 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-04-10 · NCT06622005 · CT.gov ↗
What to watch
Phase 4Acquired HemophiliaRecruiting
Est. primary completion 2027-04-30 · NCT05849740 · CT.gov ↗
What to watch
May 2027 (4)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-05 · NCT04176718 · CT.gov ↗
What to watch
Early phase / not applicableMultiple MyelomaNot yet recruiting
Est. primary completion 2027-05 · NCT07721350 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-05-17 · NCT03346135 · CT.gov ↗
What to watch
Phase 4ITP - Immune ThrombocytopeniaRecruiting
Est. primary completion 2027-05-30 · NCT07788456 · CT.gov ↗
What to watch
June 2027 (5)
Phase 2Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06 · NCT06015724 · CT.gov ↗
What to watch
Phase 2Kidney Failure, Paraproteinemias, GlomerulonephritisRecruiting
Est. primary completion 2027-06 · NCT06889948 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-06 · NCT05572229 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaNot yet recruiting
Est. primary completion 2027-06-29 · NCT07191379 · CT.gov ↗
What to watch
Phase 2T-cell Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-06-30 · NCT05289687 · CT.gov ↗
What to watch
July 2027 (4)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-07 · NCT03556332 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-07-01 · NCT04124497 · CT.gov ↗
What to watch
Phase 2Plasmablastic LymphomaRecruiting
Est. primary completion 2027-07-01 · NCT04915248 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-07-30 · NCT05455320 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-08 · NCT04497961 · CT.gov ↗
What to watch
September 2027 (3)
Phase 1T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic LymphomaRecruiting
Est. primary completion 2027-09 · NCT04972942 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-09 · NCT06398457 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-09-08 · NCT04635189 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10 · NCT03004287 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10-30 · NCT03763162 · CT.gov ↗
What to watch
November 2027 (5)
Phase 2Immune Thrombocytopenia, TreatmentRecruiting
Est. primary completion 2027-11 · NCT07297563 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-11 · NCT07018050 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-11-01 · NCT06142396 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-11-16 · NCT04975997 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaRecruiting
Est. primary completion 2027-11-30 · NCT06409702 · CT.gov ↗
What to watch
December 2027 (7)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12-20 · NCT04775550 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12-30 · NCT06615479 · CT.gov ↗
What to watch
Phase 1/2Aplastic Anemia, Refractory, RelapseRecruiting
Est. primary completion 2027-12-31 · NCT07287228 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT06107738 · CT.gov ↗
What to watch
Phase 2AL AmyloidosisRecruiting
Est. primary completion 2027-12-31 · NCT07335887 · CT.gov ↗
What to watch
Phase 2Antibody-mediated Rejection, Antibody-Mediated Rejection (AMR)Active not recruiting
Est. primary completion 2027-12-31 · NCT07902609 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT04566328 · CT.gov ↗
What to watch
2028 (22)
February 2028 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-02 · NCT04661137 · CT.gov ↗
What to watch
Phase 2Light-chain Cardiac AmyloidosisNot yet recruiting
Est. primary completion 2028-02-01 · NCT07743957 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-02-28 · NCT06948084 · CT.gov ↗
What to watch
March 2028 (5)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03 · NCT07221032 · CT.gov ↗
What to watch
Phase 2Immune Thrombocytopenia, TreatmentRecruiting
Est. primary completion 2028-03 · NCT07362238 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07341867 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07045909 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2028-04-26 · NCT06353022 · CT.gov ↗
What to watch
May 2028 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-05 · NCT07485647 · CT.gov ↗
What to watch
Phase 1/2Autoimmune DisordersRecruiting
Est. primary completion 2028-05-05 · NCT05671757 · CT.gov ↗
What to watch
July 2028 (2)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2028-07 · NCT07742215 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-07-30 · NCT07638683 · CT.gov ↗
What to watch
August 2028 (3)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2028-08 · NCT05434689 · CT.gov ↗
What to watch
Phase 2Proliferative Glomerulonephritis With Monoclonal IgG DepositsActive not recruiting
Est. primary completion 2028-08 · NCT05654506 · CT.gov ↗
What to watch
Phase 1Adult Patients With Adverse Risk Acute Myeloblastic LeukemiaRecruiting
Est. primary completion 2028-08-06 · NCT05749276 · CT.gov ↗
What to watch
September 2028 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2028-09 · NCT05231629 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-09-15 · NCT05695508 · CT.gov ↗
What to watch
October 2028 (1)
Phase 1/2Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)Not yet recruiting
Est. primary completion 2028-10-29 · NCT07110662 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Immune Thrombocytopenia, TreatmentRecruiting
Est. primary completion 2028-11 · NCT07234019 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-12-21 · NCT04910568 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-12-31 · NCT06100237 · CT.gov ↗
What to watch
2029 (19)
January 2029 (5)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2029-01-02 · NCT06768489 · CT.gov ↗
What to watch
Phase 2Primary Plasma Cell LeukemiaRecruiting
Est. primary completion 2029-01-05 · NCT06636552 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07085728 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07764978 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-01-31 · NCT05438043 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-03-01 · NCT05896228 · CT.gov ↗
What to watch
April 2029 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-04 · NCT07107529 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2029-04-15 · NCT07830485 · CT.gov ↗
What to watch
May 2029 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-05-05 · NCT07891923 · CT.gov ↗
What to watch
Phase 1Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic SyndromeRecruiting
Est. primary completion 2029-05-19 · NCT06287944 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-05-21 · NCT07222761 · CT.gov ↗
What to watch
July 2029 (2)
Phase 1Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma …Recruiting
Est. primary completion 2029-07 · NCT04139304 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2029-07-24 · NCT07099391 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2CancerRecruiting
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2T-Lymphocytic Leukemia, AcuteActive not recruiting
Est. primary completion 2029-10 · NCT06253637 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2AL AmyloidosisRecruiting
Est. primary completion 2029-11-30 · NCT05898646 · CT.gov ↗
What to watch
December 2029 (3)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2029-12 · NCT05527340 · CT.gov ↗
What to watch
Phase 1T-cell Acute Lymphoblastic Leukemia, LymphomaRecruiting
Est. primary completion 2029-12-31 · NCT07513129 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-12-31 · NCT03937635 · CT.gov ↗
What to watch
2030 (8)
April 2030 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-04-01 · NCT07029776 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3AL AmyloidosisRecruiting
Est. primary completion 2030-07-29 · NCT06022939 · CT.gov ↗
What to watch
September 2030 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2030-09-02 · NCT06577025 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2030-09-04 · NCT07665450 · CT.gov ↗
What to watch
October 2030 (2)
Phase 1/2Plasma Cell DisorderRecruiting
Est. primary completion 2030-10-01 · NCT07075510 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2030-10-18 · NCT05623020 · CT.gov ↗
What to watch
December 2030 (2)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2030-12 · NCT06953960 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-12-01 · NCT07247097 · CT.gov ↗
What to watch
2031 (9)
January 2031 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-01 · NCT06187441 · CT.gov ↗
What to watch
February 2031 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2031-02-14 · NCT07671287 · CT.gov ↗
What to watch
March 2031 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2031-03-06 · NCT07681596 · CT.gov ↗
What to watch
April 2031 (2)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2031-04-01 · NCT06785415 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-04-30 · NCT05552222 · CT.gov ↗
What to watch
May 2031 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2031-05 · NCT03314181 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-05-30 · NCT05561387 · CT.gov ↗
What to watch
June 2031 (1)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2031-06-01 · NCT04513639 · CT.gov ↗
What to watch
October 2031 (1)
Phase 2AL AmyloidosisRecruiting
Est. primary completion 2031-10 · NCT07110844 · CT.gov ↗
What to watch
2032 (4)
September 2032 (2)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2032-09 · NCT04071457 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2032-09-30 · NCT06574126 · CT.gov ↗
What to watch
November 2032 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2032-11 · NCT06974786 · CT.gov ↗
What to watch
Phase 2Plasma Cell LeukemiaRecruiting
Est. primary completion 2032-11-06 · NCT07605416 · CT.gov ↗
What to watch
2033 (4)
June 2033 (2)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2033-06 · NCT05257083 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2033-06 · NCT07649525 · CT.gov ↗
What to watch
August 2033 (1)
Phase 2/3Multiple MyelomaNot yet recruiting
Est. primary completion 2033-08-01 · NCT07887984 · CT.gov ↗
What to watch
September 2033 (1)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2033-09 · NCT05259839 · CT.gov ↗
What to watch
2034 (1)
August 2034 (1)
Phase 2Lymphoma, Primary EffusionRecruiting
Est. primary completion 2034-08-01 · NCT05907759 · CT.gov ↗
What to watch
2035 (2)
September 2035 (1)
Phase 2/3Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma …Not yet recruiting
Est. primary completion 2035-09-01 · NCT07072585 · CT.gov ↗
What to watch
December 2035 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2035-12 · NCT06892522 · CT.gov ↗
What to watch
2036 (2)
May 2036 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2036-05 · NCT06918002 · CT.gov ↗
What to watch
December 2036 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2036-12 · NCT06932562 · CT.gov ↗
What to watch
2037 (1)
January 2037 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2037-01-11 · NCT07903272 · CT.gov ↗
What to watch
2041 (1)
March 2041 (1)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2041-03 · NCT07095452 · CT.gov ↗
What to watch
2042 (1)
February 2042 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2042-02 · NCT07887672 · CT.gov ↗
What to watch
2044 (1)
September 2044 (1)
Phase 2Sickle Cell DiseaseRecruiting
Est. primary completion 2044-09 · NCT06358638 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 March 2026ApprovalCHMP approves self/caregiver administration of DARZALEX SC label update
EU, EMA · Source ↗
5 March 2026ApprovalFDA approves TECVAYLI plus DARZALEX FASPRO for RRMM
US, FDA · Source ↗
27 January 2026ApprovalFDA approves DARZALEX FASPRO D-VRd for transplant-ineligible newly diagnosed multiple myeloma
US, FDA · Source ↗
9 December 2025Filing submittedsBLA submitted for TECVAYLI plus DARZALEX FASPRO in RRMM
US, FDA · Source ↗
6 November 2025ApprovalFDA approves DARZALEX FASPRO for high-risk smoldering multiple myeloma
US, FDA · Source ↗
8 December 2024Topline resultAQUILA (NCT03301220) Phase 3 met its primary endpoint
Johnson & Johnson · Source ↗